STATE STREET CORP - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 191 filers reported holding REVANCE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$26,760,749
-48.4%
2,333,108
+13.8%
0.00%
-66.7%
Q2 2023$51,905,292
-17.3%
2,050,782
+5.3%
0.00%
-25.0%
Q1 2023$62,737,446
-17.1%
1,947,763
-52.5%
0.00%
+100.0%
Q4 2022$75,671,048
+73.4%
4,099,190
+153.6%
0.00%
-33.3%
Q3 2022$43,644,000
+77.4%
1,616,453
-9.2%
0.00%
+200.0%
Q2 2022$24,597,000
-18.2%
1,779,793
+15.5%
0.00%0.0%
Q1 2022$30,058,000
+17.5%
1,541,437
-1.6%
0.00%0.0%
Q4 2021$25,571,000
-39.1%
1,566,846
+3.9%
0.00%
-50.0%
Q3 2021$42,008,000
-1.3%
1,507,838
+5.0%
0.00%0.0%
Q2 2021$42,576,000
+12.7%
1,436,444
+6.3%
0.00%0.0%
Q1 2021$37,765,000
-9.4%
1,351,166
-8.1%
0.00%
-33.3%
Q4 2020$41,668,000
+23.7%
1,470,276
+9.7%
0.00%
+50.0%
Q3 2020$33,698,000
+2.2%
1,340,406
-0.7%
0.00%0.0%
Q2 2020$32,969,000
+92.2%
1,350,080
+16.5%
0.00%0.0%
Q1 2020$17,154,000
+0.1%
1,159,055
+9.8%
0.00%
+100.0%
Q4 2019$17,129,000
+28.9%
1,055,390
+3.3%
0.00%0.0%
Q3 2019$13,288,000
+9.1%
1,022,121
+8.8%
0.00%0.0%
Q2 2019$12,180,000
-5.0%
939,072
+15.4%
0.00%0.0%
Q1 2019$12,820,000
-5.8%
813,443
+20.3%
0.00%0.0%
Q4 2018$13,612,000
-23.9%
676,222
-6.1%
0.00%0.0%
Q3 2018$17,895,000
-2.6%
720,146
+7.6%
0.00%
-50.0%
Q2 2018$18,372,000
+0.6%
669,325
+12.9%
0.00%0.0%
Q1 2018$18,259,000
+10.7%
592,910
+28.5%
0.00%
+100.0%
Q4 2017$16,491,000
+28.4%
461,360
-1.0%
0.00%0.0%
Q3 2017$12,841,000
+7.5%
466,097
+3.0%
0.00%0.0%
Q2 2017$11,944,000
+27.7%
452,490
+0.6%
0.00%0.0%
Q1 2017$9,356,000
+39.0%
449,853
+38.4%
0.00%0.0%
Q4 2016$6,729,000
+34.8%
325,148
+5.7%
0.00%0.0%
Q3 2016$4,990,000
-14.6%
307,738
-28.3%
0.00%0.0%
Q2 2016$5,840,000
-36.6%
429,482
-18.6%
0.00%0.0%
Q1 2016$9,206,000
-30.7%
527,316
+35.6%
0.00%0.0%
Q4 2015$13,281,000
+97.3%
388,796
+72.0%
0.00%0.0%
Q3 2015$6,733,000
+8.9%
226,106
+17.0%
0.00%0.0%
Q2 2015$6,185,000
+168.0%
193,221
+73.4%
0.00%
Q1 2015$2,308,000
+31.4%
111,425
+7.4%
0.00%
Q4 2014$1,756,000
-8.3%
103,742
+4.9%
0.00%
Q3 2014$1,914,000
-38.3%
98,859
+8.4%
0.00%
Q2 2014$3,103,000
+50.4%
91,229
+39.3%
0.00%
Q1 2014$2,063,00065,4950.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
NovaQuest Capital Management, L.L.C. 1,558,426$48,000,00065.50%
Essex Woodlands Management, Inc. 3,842,047$118,335,00025.90%
Rhenman & Partners Asset Management AB 203,181$6,258,0000.77%
EAM Global Investors LLC 44,898$1,383,0000.72%
Fosun International Ltd 319,313$9,835,0000.62%
EAM Investors, LLC 113,096$3,483,0000.58%
ArrowMark Colorado Holdings LLC 1,735,699$53,460,0000.53%
Perceptive Advisors 618,957$19,064,0000.53%
ESSEX INVESTMENT MANAGEMENT CO LLC 111,360$3,430,0000.45%
Schonfeld Strategic Advisors LLC 83,700$2,578,0000.19%
View complete list of REVANCE THERAPEUTICS INC shareholders